Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LUCAT1 siRNA
- Development stage
- Preclinical
- Lead developer
- Chang Gung University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
LUCAT1 siRNA is a small interfering RNA designed to silence the long non-coding RNA (lncRNA) LUCAT1 (Lung Cancer Associated Transcript 1). In the context of head and neck cancer (HNC), LUCAT1 is upregulated by areca nut components, such as arecoline, via STAT1 activation. Silencing LUCAT1 with siRNA has been shown to inhibit cell invasion by modulating epithelial-mesenchymal transition (EMT) and to reverse chemo-radiotherapy resistance by regulating reactive oxygen species (ROS) scavenging and autophagy. It is primarily used as a research tool to investigate the oncogenic roles of LUCAT1 in various cancers, including HNC and lung cancer.
- Other names
- siRNA targeting LUCAT1LUCAT1-silencing siRNALUCAT-1-silencing siRNALUCAT 1-silencing siRNAsi-LUCAT1si-LUCAT-1si-LUCAT 1
02
Targets
LUCAT1 (Lung cancer associated transcript 1)
Beyond the preview
Go deeper on LUCAT1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LUCAT1 siRNA.